AHA Coding Clinic® for HCPCS - 2014 Quarter 3; For Your Information
New HCPCS codes for certain drugs and biologicals
New HCPCS codes for the reporting of certain drugs and biologicals were effective October 1, 2014. The new HCPCS codes are listed in the table below. HCPCS code HCPCS Long descriptor C9023 Injection, testosterone undecanoate, 1 mg C9025 Injection, ramucirumab, 5 mg C9026 Injection, vedolizumab, 1 mg C9135 Factor ix (antihemophilic factor, recombinant), Alprolix, per i.u. Q9972 Injection, Epoetin Beta, 1 microgram, (For ESRD On Dialysis) Q9973 Injection, Epoetin Beta, 1 microgram, (Non-ESRD use) ...
Subscribe or sign in to view the full article.
Article Overview
This brief coding update covers new HCPCS reporting codes for certain drugs and biologicals effective October 1, 2014. It is useful for billing, coding, and reimbursement professionals who need to track changes in drug-related HCPCS reporting and understand which new identifiers were added.
Why This Topic Matters
Updates to HCPCS drug and biological reporting can affect claims processing, charge capture, and code maintenance. Readers in hospital, outpatient, pharmacy, and physician billing workflows may need this information to stay current with code set changes.
What You Will Learn
- Which HCPCS drug and biological reporting codes became effective on the stated date.
- The general scope of the update and the types of products covered.
- How the article presents the new HCPCS additions in tabular form.
- Which clinical and billing areas may be affected by the update.
Who Should Read This
- Medical coders
- Billing specialists
- Revenue cycle staff
- Compliance staff
- Healthcare administrators
- Pharmacy billing professionals
Codes Discussed
Subscribe or sign in to view the full article.

Quick, Current, Complete - www.findacode.com